MET and melanoma: While treatment with BRAF- and MEK-inhibitors is not sufficient to overcome HGF-induced resistance, BRAF- and MET (the HGF receptor)-inhibitors suppress the majority of HGF-induced drug resistance in BRAF-mutant melanoma [89,90].